second-quart full year guidanc signific
catalyst drive valu beyond
wednesday juli market close gilead report second quarter
financi result exhibit demonstr bounc back hiv franchis
first quarter stabil hcv franchis revenu quarter
billion estim billion consensu billion hiv franchis
revenu came billion beat consensu estim billion
repres growth first quarter world-wide hcv revenu billion
consensu estim million demonstr sequenti declin
stabil first-quart revenu billion yescarta sale
million beat estim million consensu estim million
bottom line non-gaap ep quarter beat estim
consensu larg due lower effect tax rate quarter favor
settlement tax examin complet varianc analysi expect
consensu actual result quarter summar exhibit
note second quarter hiv beat estim driven favor payer
mix strong launch biktarvi stabil inventori channel result
increas hiv product sale billion billion previous
hcv franchis exhibit stabil first quarter manag expect slow
steadi declin move forward continu estim hcv product sale
billion lastli yescarta roll-out occur faster anticip result
increas yescarta sale million million previous
base chang lower non-gaap effect tax rate rang
guidanc increas full year product revenu billion
billion previous rais full year non-gaap ep
manag reiter total revenu guidanc billion
well guidanc gross margin expens sg expens manag
also reduc guidanc effect tax rate
return equiti ttm
gilead research-bas biotechnolog compani focus develop therapi treatment life-
threaten diseas gilead leader hiv/aid therapeut recent hcv also
larg product portfolio includ therapeut liver cardiovascular inflammatori respiratori diseas
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
continu hold long-term posit view gilead share due strong hiv franchis growth stabil
hcv franchis dividend yield promis cell therapi field major upcom phase data readout
potenti bring top line novel technolog pipelin candid sum-of-the-part
valuat analysi show fair valu exhibit model continu recogn year
rel flat year return growth dcf analys hiv hcv franchis lead
valuat per share respect late-stag asset expect read phase data
valu filgotinib per share probabl success rheumatoid arthriti probabl success
ulcer coliti crohn diseas valu selonsertib per share advanc nash probabl
success addit valu yescarta next gener product candid per share includ per share
net cash year-end deriv fair valu estim gilead share
base current trajectori strong uptak first quarter biktarvi set overtak genvoya
top hiv agent support gilead continu hiv franchis domin exhibit biktarvi b/f/taf
approv februari mark compani eighth final combin regimen develop hiv
platform lifelong control hiv infect first full quarter market biktarvi brought million
volum come switch patient came patient previous dolutegravir-
contain regimen came genvoya patient rapid rate adopt biktarvi exceed
genvoya previous grab top spot launch uptak among hcv regimen unlik genvoya
requir pharmacokinet booster cobicistat biktarvi need booster improv safeti
profil posit biktarvi becom primari option treatment-nav switch patient march
biktarvi ad depart human servic guidelin use anti-retrovir
agent adult adolesc live hiv one recommend initi regimen earlier week
journal american medic associ publish updat treatment guidelin aid
societi biktarvi recommend addit total hiv script volum increas year-over-year reflect
gilead preemin field continu expect compani hiv franchis continu hold absolut
domin hiv market current market share grow forecast
sustain growth first next-gener taf-bas regimen begin lose patent
sequenti declin first quarter hcv revenu stabil second quarter slight
sequenti growth manag continu expect hcv market fulli stabil year-end
exhibit competit outperform appear stabil market share
expect reach equilibrium follow slow steadi overal declin market contract
continu ascrib matur market share mavyret gilead franchis due mavyret simpl
algorithm competit profil long term current project sale hcv franchis
gilead billion potenti upsid gilead estim could come sale
hcv franchis product china intern market
yescarta second full quarter market beat expect million book competit
continu intensifi make execut key continu success novarti nv gilead race
launch respect lead car-t kymriah yescarta across transplant center unit state
second quarter novarti book million sale kymriah due smaller address
popul pediatr acut lymphoblast leukemia follow kymriah approv r/r dlbcl may
expect competit intensifi gilead achiev author center end second
quarter estim roughli center need cover elig r/r dlbcl patient
unit state first-mov advantag set base compani site activ trajectori
geography-bas strategi roughli patient within reason distanc certifi transplant
center current europ follow approv yescarta compani plan complet author
center germani franc
look numer near-term catalyst sustain share price out-performance drive growth beyond
declin hcv franchis sale eu approv yescarta aggress nhl anticip come third
quarter data first three phase studi filgotinib rheumatoid arthriti anticip
second half follow readout remain studi could
lead first regulatori file asset nash expect phase ii data studi fxr agonist
fourth quarter follow data two phase studi inhibitor selonsertib first half
phase studi evalu selonsertib monotherapi nash patient
bridg fibrosi cirrhosi respect posit trial could lead regulatori file selonsertib
end phase iib combin studi selonsertib /- /- inhibitor advanc
nash expect read interim data second half beyond candid gilead continu
pursu develop broad pipelin span hiv hbv liver diseas immunolog oncolog well
label expans approv agent
strateg develop deploy capit remain key goal continu believ gilead provid
long-term opportun valu growth strong investor return includ dividend yield
robust share buy-back program manag continu comment compani continu evalu strateg
deal priorit use capit invest long-term growth recent exemplifi recent
collabor deal sangamo verili gadeta view oncolog liver diseas
inflamm area high interest develop believ addit strateg acquisit could take
place near futur enhanc compani pipelin bolster growth
risk outperform thesi includ compani depend hiv franchis repres fundament
concentr risk investor magnitud speed declin hcv franchis launch yescarta could miss
expect safeti risk market could lead stock volatil continu pipelin expans cellular therapi
clinic risk filgotinib selonsertib phase studi pipelin asset
hcv product royalti contract total sg total oper interest expens incom expens pre-tax provis incom net net incom loss attribut non-controlling net incom attribut non- reconciliationcost good sold expens sg expens interest expens adjustments- total non- adjust incom tax effect tax reform total non- adjust non- net incom attribut non- dividend per common weight averag share outstand weight averag share outstand compani report william blair scienc inc incom statement william blair
actualwb estimatespreadvarianceq/q growthy/i growthcon hcv hiv product cost expensescost good gener net incom attribut ep compani report william blair estimatescurr scienc inc current quarter varianc analysi dollar million except ep william blair
drugpeak sale stage ofdevelopmentestimatedlaunch dateprob commercializationpercentag sale companyprobability-adjust npvvalu per sharepercentag fair valuehiv phase phase year-end present valu addit loss fair includ cost directli relat program abovesourc william blair estimatesexhibit scienc inc fair valuesourc compani report william blair estimatesexhibit scienc inc hiv franchis revenu regimen regimenstaf regimensatriplatruvadacompleraodefseydescovystribildgenvoyab/f/tafu patent expir date william blair
sourc compani report william blair estimatesexhibit scienc inc hcv global market import disclosur
